INTRODUCTION AND OBJECTIVES:
We have previously reported a decreased incidence and delay in vesico-ureteral reflux (VUR) diagnosis since the 2011 American Academy of Pediatrics (AAP) guidelines were released. We hypothesized that delay in diagnosis has led to an increased risk of repeat urinary tract infection (UTI) or pyelonephritis episodes prior to the diagnosis of underlying VUR.
METHODS: We performed our analysis using Cliniformatics TM Data Mart (Optuminsight, Eden Prairie, MN) administrative claims data from January 2007 to December 2016. Children 0 to 10 years of age who were diagnosed with VUR were included. All emergency department encounters with UTI or pyelonephritis diagnosis codes prior to initial VUR diagnosis were recorded. Pearson's chi-squared test was used to test for an association between multiple UTI or pyelonephritis related emergency department encounters and VUR diagnosis before or after the release of the 2011 AAP guidelines (September 2011). RESULTS: A total of 1,314 patients with underlying VUR presented to the emergency department prior to their diagnosis. In the pre-AAP cohort, 822 patients presented to the emergency department, and in the post-AAP cohort 428 patients presented to the emergency department. Children diagnosed with VUR after the 2011 AAP guidelines were more likely to present with multiple UTI or pyelonephritis related emergency department encounters prior to VUR diagnosis (p [ 0.002). Of the post-AAP cohort, 13.0% of the post-AAP cohort had multiple UTI or pyelonephritis related emergency department visits compared to 7.8% of the pre-AAP cohort (OR [ 1.77, 95% CI 1.21 -2.60). Children 0 -2 years of age diagnosed with VUR after the 2011 AAP guidelines were also more likely to present with multiple emergency department visits prior to diagnosis (p [ 0.02; 6.8% versus 3.0% (OR [ 2.35, 95% CI 1.08 -5.18)).
CONCLUSIONS: Children with underlying VUR may be at higher risk of multiple UTI or pyelonephritis emergency room episodes prior to initial diagnosis since the release of the 2011 AAP guidelines. This is a consequence of delayed diagnosis in children with underlying VUR. However, there may be subgroups in whom AP is either more or less effective. If they were identifiable, AP could be used more selectively. We sought to develop a machine learning model to identify such subgroups in RIVUR.
METHODS: RIVUR data were randomly split into train/test sets in 4:1. Two optimal classification tree models were built for AP and non-AP subgroups to predict rUTI risk in both scenarios. The test set was then used to validate actual rUTI events and the effectiveness of AP. Two predicted probabilities were generated from each prediction model and AP was assigned according to cutoffs for AP treatment effectiveness defined by rUTI risk difference.
RESULTS: 607 patients (558 female/49 male, median age 12 mo) were included. Predictor variables in the model included VUR grade, serum creatinine, race/sex, prior UTI symptoms (fever, dysuria), and weight percentiles. The AUC of the joint prediction model of rUTI by treatment arms (AP vs placebo, Figure 1 ) was 0.81(0.75-0.86). Figure 2 compares the rUTI rate for randomly assigned AP (dashed lines) versus assignment by the model using risk reduction cutoffs (solid line). Using the model to assign AP based on >10% rUTI risk reduction, similar population efficacy can be achieved by treating only 40% of VUR patients compared to treating everyone.
In a 120-patient test set, 51 patients had actual AP randomization consistent with our model recommendation (AP if absolute rUTI risk reduction > 10%). Actual rUTI incidence was significantly lower among those whose AP randomization was consistent with our model suggestion, compared to those whose AP assignment differed from model suggestion (2 vs 12.9%, p[0.03).
CONCLUSIONS: Our predictive model using machine learning algorithms identifies VUR patients who are more likely to benefit from AP, which would allow more selective, personalized use of AP with maximal benefit, while minimizing use in those least likely to benefit.
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